Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
VLUE vs XBI: how they differ
VLUE and XBI hold 0% of their weight in the same names, and VLUE returned more over the year.
iShares MSCI USA Value Factor ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, VLUE and XBI hold 0% of their money in the same securities at the same weight.
| Holding | VLUE | XBI |
|---|---|---|
| BIOGEN INC. | 0.27% | 1.03% |
| UNITED THERAPEUTICS CORPORATION | 0.18% | 0.93% |
| Only in VLUE | Only in XBI |
|---|---|
| MICRON TECHNOLOGY, INC. 11.63% | Apogee Therapeutics Inc 1.49% |
| INTEL CORPORATION 9.29% | Moderna Inc 1.41% |
| CISCO SYSTEMS, INC. 4.97% | Twist Bioscience Corp 1.41% |
| APPLIED MATERIALS, INC. 3.67% | Oruka Therapeutics Inc 1.38% |
| GENERAL MOTORS COMPANY 3.16% | Kymera Therapeutics Inc 1.36% |
| VERIZON COMMUNICATIONS INC. 2.66% | Viking Therapeutics Inc 1.31% |
| AT&T INC. 2.53% | Praxis Precision Medicines Inc 1.29% |
| CITIGROUP INC. 1.94% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Jun 30, 2026.
| VLUE iShares MSCI USA Value Factor ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | MSCI USA Value Factor | SPDR S&P Biotech |
| Total return, 1 year | +69.4% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +51.9 pts | +46.5 pts |
| Expense ratio | 0.15% | 0.35% |
| Already in the S&P 500 | 96.9% | 8.5% |
| Holdings | 148 | 150 |
VLUE in plain words
VLUE is an index equity fund tracking the MSCI USA Value Factor. Over the year to Sep 11, 2026 it returned +69.4% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.15% a year. By its holdings filed for Apr 30, 2026, 97% of the fund by weight is stocks the S&P 500 also holds, across 148 positions, with the top ten at 43.6%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, VLUE or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, VLUE returned +69.4% and XBI returned +64.0%, so VLUE returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, VLUE or XBI?
- VLUE charges 0.15% a year and XBI charges 0.35%, so VLUE is cheaper. Fees come from each fund's prospectus.
- How much do VLUE and XBI overlap with the S&P 500?
- By their latest filed holdings, 97% of VLUE and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, VLUE against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/VLUE-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources